A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancerPanagiotis A. Konstantinopoulos, Ronnie Shapira‐Frommer, Ignace Vergote et al.|Gynecologic Oncology|2022Cited by 66
A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung CancerLauren A. Byers, Martin Förster, Alejandro Navarro et al.|Clinical Lung Cancer|2021Cited by 39
A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic CancerKathleen N. Moore, Johanna C. Bendell, David S. Hong et al.|Targeted Oncology|2021Cited by 25